Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis

Phase 2 Not yet recruiting 39 enrolled Institute of Hematology & Blood Diseases Hospital, China

NaSingle-groupOpen-labelPrevention

Summary

The investigators evaluate the efficacy and safety of Gecacitinib in patients with myelofibrosis (MF) before, during, and after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Timeline

Start: 2026-03-16
Primary completion: 2029-04-01
Completion: 2030-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gecacitinib	Unknown	100 mg	—

Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis

Summary

Timeline

Drugs

Indications